- Wednesday, March 29, 2023
7:00 AM – 8:00 AM
CE Symposia: Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
7:00 AM – 8:00 AM
CE Symposia: Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed InitiativesLocation: 159*Speaker: – The Hospital of the University of Pennsylvania
*Speaker:
*Speaker: – University of California, Irvine
Craig Freyer, PharmD, BCOP – The Hospital of the University of Pennsylvania ### 894758###*Speaker###Clinical Pharmacy Specialist in Hematology/Oncology, Allogeneic Stem Cell Transplant, and Cellular Therapy###The Hospital of the University of Pennsylvania###*Speaker: – The Hospital of the University of Pennsylvania
### @@@ Katie Gatwood, PharmD, BCOP ### 1545829###*Speaker#########*Speaker:
### @@@ Shawn P. Griffin, PharmD, BCOP (he/him/his) – University of California, Irvine ### 1772980###*Speaker###Assistant Clinical Professor###University of California, Irvine###*Speaker: – University of California, Irvine
### he/him/his7:00 AM – 8:00 AM
CE Symposia: Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
7:00 AM – 8:00 AM
CE Symposia: Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful RoleLocation: 158*Speaker:
*Speaker: – University of North Carolina Eshelman School of Pharmacy
*Speaker: – UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences
Mimi Lo, PharmD, BCPS, BCOP ### 1894946###*Speaker#########*Speaker:
### @@@ Benyam Muluneh, PharmD, BCOP, CPP – University of North Carolina Eshelman School of Pharmacy ### 1137104###*Speaker###Clinical-Assistant Professor###University of North Carolina Eshelman School of Pharmacy###*Speaker: – University of North Carolina Eshelman School of Pharmacy
### @@@ Ila Saunders, PharmD, BCOP – UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences ### 900571###*Speaker###Assistant Clinical Professor###UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences###*Speaker: – UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences
### 8:00 AM – 12:00 PM
Pre-Conference: Precision Medicine in Oncology
8:00 AM – 12:00 PM
001 - Pre-Conference: Precision Medicine in OncologyLocation: 150-151Speaker: – UNC Health
Co-Speaker: – Mayo Clinic
Co-Speaker: – Department of Veterans Affairs
Pre-Conference (Special Fee)
Amber B. Cipriani, PharmD, BCOP – UNC Health ### 1609190###Speaker###Precision Medicine Pharmacy Coordinator###UNC Health###Speaker: – UNC Health
### @@@ Sara Maloney, PharmD, BCOP, MHSA (she/her/hers) – Mayo Clinic ### 1820763###Co-Speaker###Precision Oncology and Research Support Pharmacist###Mayo Clinic###Co-Speaker: – Mayo Clinic
### she/her/hers @@@ Jill Bates, PharmD, MS, BCOP, FASHP – Department of Veterans Affairs ### 1820764###Co-Speaker###Acting Deputy Executive Director National Pharmacogenomics Program###Department of Veterans Affairs###Co-Speaker: – Department of Veterans Affairs
###
12:00 PM – 1:00 PM
Non-CE Symposia: Advances in CLL Therapy: Practical Management of a BCL2-Inhibitor
12:00 PM – 1:00 PM
Non-CE Symposia: Advances in CLL Therapy: Practical Management of a BCL2-InhibitorLocation: 157*Speaker: – Boston Medical Center
Jasmine Patel, PharmD, BCOP – Boston Medical Center ### 947640###*Speaker###Clinical Pharmacy Specialist###Boston Medical Center###*Speaker: – Boston Medical Center
### 12:00 PM – 1:00 PM
Non-CE Symposia: How Is the Treatment of Patients With KRAS G12C-Mutated Advanced NSCLC Evolving?
12:00 PM – 1:00 PM
Non-CE Symposia: How Is the Treatment of Patients With KRAS G12C-Mutated Advanced NSCLC Evolving?Location: 159
Sandra Cuellar, PharmD BCOP ### 957901###*Speaker#########*Speaker:
### 12:00 PM – 1:00 PM
Non-CE Symposia: Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care
12:00 PM – 1:00 PM
Non-CE Symposia: Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care Location: 158*Speaker: – The Hospital of the University of Pennsylvania
Craig Freyer, PharmD, BCOP – The Hospital of the University of Pennsylvania ### 894758###*Speaker###Clinical Pharmacy Specialist in Hematology/Oncology, Allogeneic Stem Cell Transplant, and Cellular Therapy###The Hospital of the University of Pennsylvania###*Speaker: – The Hospital of the University of Pennsylvania
### 12:00 PM – 1:00 PM
What's the Scoop with the Board of Directors?
12:00 PM – 1:00 PM
What's the Scoop with the Board of Directors?
Location: Ballroom Lobby
1:15 PM – 2:15 PM
Early-Stage Breast Cancer – Updates in Management
1:15 PM – 2:15 PM
BC1 - Updates in Early-Stage Breast Cancer Location: BallroomSpeaker: – West Virginia University Medicine
BCOP
Jordan Hill, PharmD, BCOP – West Virginia University Medicine ### 1772979###Speaker###Clinical Pharmacy Specialist - Oncology###West Virginia University Medicine###Speaker: – West Virginia University Medicine
###
1:15 PM – 2:15 PM
Updates in the Management of Follicular and Mantle Cell Lymphomas
1:15 PM – 2:15 PM
101 - Updates in the Management of Follicular and Mantle Cell Lymphomas Location: 160-163Speaker: – UT MD Anderson Cancer Center
Brian Primeaux, PharmD, BCOP (he/him/his) – UT MD Anderson Cancer Center ### 1774213###Speaker###Clinical Pharmacy Specialist###UT MD Anderson Cancer Center###Speaker: – UT MD Anderson Cancer Center
### he/him/his
2:00 PM – 3:00 PM
President’s Welcome and Recognition of 2023 HOPA Fellows
2:30 PM – 3:00 PM
President’s Welcome and Recognition of 2023 HOPA FellowsLocation: Ballroom
Heidi D. Finnes, PharmD, BCOP, FHOPA – Mayo Clinic ### 1181746###Presenter###Senior Manager Pharmacy Cancer Research###Mayo Clinic###Presenter: – Mayo Clinic
### 3:15 PM – 4:15 PM
Platform Research: Bruton Tyrosine Kinase (BTK) Inhibitors: Real World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital
3:15 PM – 3:30 PM
102 - Bruton Tyrosine Kinase (BTK) Inhibitors: Real World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net HospitalLocation: BallroomCo-Speaker: – Boston Medical Center
Co-Speaker: – Boston Medical Center; Boston University School of Medicine
Research
Lynnette Henshaw, PharmD, BCOP – Boston Medical Center ### 1252186###Co-Speaker###Clinical Pharmacy Specialist-Hematology/Oncology###Boston Medical Center###Co-Speaker: – Boston Medical Center
### @@@ Camille Edwards, MBBS (she/her/hers) – Boston Medical Center; Boston University School of Medicine ### 1835778###Co-Speaker###Clinical Hematologist, Assistant Professor###Boston Medical Center; Boston University School of Medicine###Co-Speaker: – Boston Medical Center; Boston University School of Medicine
### she/her/hers
3:15 PM – 4:15 PM
Platform Research: Clinical Pharmacist-Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
3:30 PM – 3:45 PM
102 - Clinical Pharmacist-Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid LeukemiaLocation: BallroomPresenter: – Kaiser Permanente-Colorado
Research
Jared Freml, PharmD, BCOP – Kaiser Permanente-Colorado ### 1835776###Presenter###Clinical Pharmacy Specialist-Oncology###Kaiser Permanente-Colorado###Presenter: – Kaiser Permanente-Colorado
###
3:15 PM – 4:15 PM
Platform Research: Knowledge Gaps and Educational Needs for Common Cancer Therapy-Related Cardiovascular Toxicities and Related Drug Interactions
3:45 PM – 4:00 PM
102 - Knowledge Gaps for Cancer Therapy-Related Cardiovascular ToxicitiesLocation: BallroomCo-Speaker: – Duke University Medical Center
Research
Kristen T. Peterson, PharmD, BCOP – Duke University Medical Center ### 1835777###Co-Speaker###Clinical Oncology Pharmacist###Duke University Medical Center###Co-Speaker: – Duke University Medical Center
###
3:15 PM – 4:15 PM
Platform Research: Optimizing Corticosteroid Utilization for Immune-related Adverse Events at a Community Oncology Practice
4:00 PM – 4:15 PM
102 - Optimizing Corticosteroid Utilization for Immune-related Adverse Events at a Community Oncology PracticeLocation: BallroomPresenter: – Cancer & Hematology Centers of Western Michigan
Research
Christin M. Molnar, PharmD, BCOP (she/her/hers) – Cancer & Hematology Centers of Western Michigan ### 1511234###Presenter###Research Pharmacy Manager###Cancer & Hematology Centers of Western Michigan###Presenter: – Cancer & Hematology Centers of Western Michigan
### she/her/hers
4:30 PM – 5:30 PM
Significant Updates in Oncology
4:30 PM – 5:30 PM
103 - Significant Updates in OncologyLocation: 160-163Speaker: – ETSU Bill Gatton College of Pharmacy
John Bossaer, PharmD, BCOP (he/him/his) – ETSU Bill Gatton College of Pharmacy ### 1171474###Speaker###Professor###ETSU Bill Gatton College of Pharmacy###Speaker: – ETSU Bill Gatton College of Pharmacy
### he/him/his
4:30 PM – 5:30 PM
Updates in Hepatocellular Carcinoma
4:30 PM – 5:30 PM
BC2 - Updates in Hepatocellular CarcinomaLocation: BallroomSpeaker: – Vanderbilt University Medical Center
BCOP
Sarah K. Cimino, PharmD, BCPS, BCOP – Vanderbilt University Medical Center ### 1774205###Speaker###Clinical Pharmacist Specialist, Gastrointestinal Oncology###Vanderbilt University Medical Center###Speaker: – Vanderbilt University Medical Center
###
5:30 PM – 6:30 PM
Committee Networking Reception
5:30 PM – 6:30 PM
Committee Networking Reception
Location: Networking Lounge
5:30 PM – 7:30 PM
Welcome Reception
5:30 PM – 7:30 PM
Welcome Reception
Location: Exhibit Hall
5:45 PM – 6:30 PM
2023 Annual Advocacy Update (Non-CE)
5:45 PM – 6:30 PM
2023 Annual Advocacy Update (Non-CE)Location: BallroomCo-Speaker: – HOPA
Co-Speaker: – The Ohio State University Wexner Medical Center
Co-Speaker: – CRD Associates
Co-Speaker: – The University of Kansas Health System
Advocacy
Brooke Boring, MPH, CPhT (she/her/hers) – HOPA ### 1518390###Co-Speaker###Senior Manager of Health Policy & Advocacy###HOPA###Co-Speaker: – HOPA
### she/her/hers @@@ Jeff Pilz, PharmD, MPA, MS, BCPS – The Ohio State University Wexner Medical Center ### 1518389###Co-Speaker###Assistant Director of Pharmacy - Medication Safety and Drug Policy###The Ohio State University Wexner Medical Center###Co-Speaker: – The Ohio State University Wexner Medical Center
### @@@ Jeremy Scott, MA – CRD Associates ### 969263###Co-Speaker###Senior Vice President###CRD Associates###Co-Speaker: – CRD Associates
### @@@ Taylor Monson, PharmD, BCOP, BCPS (she/her/hers) – The University of Kansas Health System ### 1837553###Co-Speaker###Clinical Oncology Pharmacist###The University of Kansas Health System###Co-Speaker: – The University of Kansas Health System
### she/her/hers
6:30 PM – 7:15 PM
Non-CE Symposia: Evolving CLL Treatment Paradigms Exploring Chemo Free Regimens With A Fixed Treatment Duration
6:30 PM – 7:15 PM
Non-CE Symposia: Evolving CLL Treatment Paradigms Exploring Chemo Free Regimens With A Fixed Treatment DurationLocation: 159
Vincent Herrin, MD ### 1895967###*Speaker#########*Speaker:
### 6:30 PM – 7:15 PM
Non-CE Symposia: Treatment Options for Patients with Unresectable or Metastatic Melanoma
6:30 PM – 7:15 PM
Non-CE Symposia: Treatment Options for Patients with Unresectable or Metastatic MelanomaLocation: 158
Kevin McWilliams, PharmD ### 1917214###*Speaker#########*Speaker:
### 6:30 PM – 7:30 PM
LGBTQ+ Reception
6:30 PM – 7:30 PM
LGBTQ+ Reception
Location: 150-151
